In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Advaxis (ADXS), with a price target of $2. The company’s shares closed yesterday at $0.54, close to its 52-week low of $0.47.
Ramakanth commented:
“We maintain our Buy rating and our $2.00 per diluted share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple (6x 2026 sales estimate at 14% discount); and 2) price-earnings multiple (19x 2026 earnings estimate at 14% discount).”
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.2% and a 35.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Advaxis with a $2 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.58 and a one-year low of $0.47. Currently, Advaxis has an average volume of 825.3K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADXS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins.
